Brief: Inogen Q2 Revenue USD 92.3 Million

Inogen

07/08/2025 21:22

Overview

Inogen Q2 2025 revenue rises 4% yr/yr, beating analyst expectations, per LSEG data

Adjusted net loss for Q2 improves to $0.7 mln, beating analyst estimates, per LSEG data

Co raises full-year 2025 revenue guidance, expects adjusted EBITDA breakeven

Outlook

Inogen raises full-year 2025 revenue guidance to $354 mln-$357 mln

Company expects full-year 2025 Adjusted EBITDA breakeven

Inogen projects Q3 2025 revenue of $91 mln-$93 mln

Company sees 4% year-over-year growth in Q3 2025 revenue

Result Drivers

BUSINESS-TO-BUSINESS GROWTH - Revenue growth driven by increased demand from international and domestic business-to-business customers

PRODUCT INTRODUCTIONS - Launch of Voxi 5 and Inogen Patient Portal aimed at expanding product offerings and improving patient engagement

REVENUE OFFSET - Growth partially offset by declines in direct-to-consumer and rental revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$92.30 mln
$90.60 mln (3 Analysts)
Q2 Adjusted Net Income
Beat
-$700,000
-$6.77 mln (3 Analysts)
Q2 Net Income
-$4.20 mln
Q2 Adjusted EBITDA
Beat
$2.10 mln
$100,000 (3 Analysts)
Q2 Gross Margin
44.8%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Inogen Inc is $13.00, about 51.5% above its August 6 closing price of $6.30

Press Release: ID:nBw9pB0q7a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)